News & Updates
Filter by Specialty:
Apalutamide for castration-resistant prostate cancer yields real-world results
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.
Apalutamide for castration-resistant prostate cancer yields real-world results
25 Mar 2022Survival for breast cancer better now than 14 years ago
Breast cancer survival has been improving greatly over the last 14 years, an effect attributable to advancements in systemic therapy, a recent Korea study has found.
Survival for breast cancer better now than 14 years ago
23 Mar 2022ADT after radiotherapy does not worsen MACE risk
Androgen deprivation therapy (ADT) does not seem to aggravate the likelihood of major adverse cardiovascular events (MACEs) in prostate cancer patients after curative radiotherapy (RT), according to a recent Singapore study.
ADT after radiotherapy does not worsen MACE risk
22 Mar 2022Novel EGFR-TKI drug shows favourable antitumour activity in NSCLC
Treatment with the novel EGFR tyrosine kinase inhibitors (EGFR-TKI) abivertinib at 300 mg twice a day appears to be effective in patients with EGFR T790M-positive nonsmall cell lung cancer (NSCLC), while having manageable side effects, according to the results of a phase II trial.